M&A Deal Summary |
|
|---|---|
| Date | 2019-08-20 |
| Target | Bayer AG - Animal Health Business |
| Sector | Consumer Services |
| Buyer(s) | Elanco |
| Sellers(s) | Bayer |
| Deal Type | Divestiture |
| Deal Value | 7.6B USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1954 |
| Sector | Life Science |
| Employees | 9,300 |
| Revenue | 4.4B USD (2023) |
Elanco develops and markets products and services to improve animal health and protein production in more than 75 countries. Elanco employs more than 3,000 people worldwide, with offices in more than 40 countries. Elanco was incorporated in 1954 and is based in Greenfield, Indiana.
| DEAL STATS | # |
|---|---|
| Overall | 10 of 11 |
| Sector (Consumer Services) | 1 of 1 |
| Type (Divestiture) | 5 of 5 |
| Country (Germany) | 3 of 3 |
| Year (2019) | 3 of 3 |
| Size (of disclosed) | 1 of 5 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-08-01 |
Prevtec Microbia
Montreal, Quebec, Canada Prevtec Microbia, Inc. is a Canadian biotechnology company developing and commercializing sustainable solutions as alternatives to antibiotics to improve animal health, production performance and food safety. Prevtec Microbia’s first commercial product, Coliprotec®F4, a swine E. coli vaccine, has been sold across Canada since 2007 and in the EU since 2015, and is approved in Brazil (2010) and in the US (2018). |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-01-13 |
Elanco Animal Health - Capstar
Greenfield, Indiana, United States Elanco Animal Health, Inc. - Capstar is an oral over-the-counter (“OTC”) flea treatment product in the United States. The Capstar portfolio is comprised of seven SKUs, including three private-label SKUs that are sold under the Capaction® brand. Capstar® is an oral tablet for the treatment of flea infestations on dogs, puppies, cats, and kittens and is currently the best-selling oral OTC flea treatment product in the United States. |
Sell | $95M |
| Category | Company |
|---|---|
| Founded | 1863 |
| Sector | Life Science |
| Employees | 98,189 |
| Revenue | 47.6B EUR (2023) |
Bayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer’s products and services are designed to benefit people and improve the quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer was founded in 1863 and is based in Leverkusen, Germany.
| DEAL STATS | # |
|---|---|
| Overall | 14 of 23 |
| Sector (Consumer Services) | 1 of 1 |
| Type (Divestiture) | 10 of 19 |
| Country (Germany) | 9 of 12 |
| Year (2019) | 4 of 4 |
| Size (of disclosed) | 1 of 10 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-08-08 |
BlueRock Therapeutics
Cambridge, Massachusetts, United States BlueRock Therapeutics LLC is a cell therapy company with a mission to develop regenerative medicines for intractable diseases. BlueRock Therapeutics’ CELL+GENE™ platform harnesses the power of cells for new medicines across neurology, cardiology and immunology indications. BlueRock Therapeutics’ cell differentiation technology recapitulates the cell’s developmental biology to produce native cell therapies, which are further engineered for additional function. Utilizing these cell therapies to replace damaged or degenerated tissue brings the potential to restore or regenerate lost function. |
Buy | $1.0B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-08-11 |
KaNDy Therapeutics
Stevenage, United Kingdom KaNDy Therapeutics is a private clinical-stage biotech based at the state-of-the-art Stevenage Bioscience Catalyst, a leading location for companies to develop and commercialize cutting edge therapeutics. KaNDy Therapeutics was formed in 2017 and is based in Stevenage, United Kingdom. |
Buy | $425M |
